Back to results
US 8,507,435 B2Granted
Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof
AssigneeXenon Pharmaceuticals Inc.
InventorsYigal Goldberg, Rajender K. Kamboj
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeXenon Pharmaceuticals Inc.
InventorsYigal Goldberg, Rajender K. Kamboj
Estimating the term…
Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. Methods for identifying modulators of HFE2A, comprising contacting a test compound with HFE2A and determining a change in HFE2A activity due to the compound, are provided. Also taught are methods of diagnosing an animal afflicted with or at risk of developing a disease of iron metabolism. Methods for treating and/or preventing a disorder in animals comprising administering to an animal afflicted therewith, or at risk of developing said disorder, a therapeutically effective amount of an HFE2A modulator are provided.
A method for treating a disease of iron metabolism comprising administering to an individual afflicted therewith a therapeutically effective amount of a modulator of an HFE2A polypeptide, wherein said modulator is selected from the group consisting of agonists to HFE2A polypeptide, antagonists to HFE2A polypeptide, a fragment of the HFE2A polypeptide, agonists to a fragment of the HFE2A polypeptide, antagonists to a fragment of the HFE2A polypeptide, including pharmaceutically acceptable salts thereof and combinations of these.
Dependencies are inferred from the claim text.